North America Cancer Diagnostics Market Outlook, 2031
The North America Cancer Diagnostics Market is segmented into By Product Type (Consumables and reagents, Instruments; By Technology (IVD testing, Anatomic pathology, Diagnostic imaging, Biopsy); By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Others); By End User (Hospitals, iagnostic Centres, Research Institutes, Others).
- Bonafide Research
- 27-10-2026
- Pages : 96
- Figures : 6
- Tables : 18
- Region : North America
- Category : Lifescience & Healthcare
- Medical Devices
- Schedule a Call
-
Sikandar Kesari — Research Analyst
The North America Cancer Diagnostics Market was valued at more than 43.07 Billion in 2025, driven by established cancer screening programmes.
- Historical Period2020-2024
- Base Year2025
- Forecast Period2026-2031
- Market Size (2025) USD 43.07 Billion
- Largest MarketUnited States
- Fastest Market Mexico
- Format
Featured Companies
- 1. Abbott Laboratories
- 2. Danaher Corporation
- 3. Siemens Healthineers
- 4. Agilent Technologies, Inc.
- 5. Thermo Fisher Scientific Inc
- 6. QIAGEN N.V.
- More...
Cancer Diagnostics Market Analysis
The North America cancer diagnostics market encompasses a sophisticated network of diagnostic tools, technologies, and clinical procedures ranging from advanced imaging systems (MRI, CT, mammography) to in vitro molecular assays, next-generation sequencing (NGS), and non-invasive liquid biopsies used to detect, stage, and monitor various malignancies. Dominating global revenue, this market holds immense relevance and critical importance due to its direct role in reducing cancer mortality; early detection drastically improves therapeutic outcomes, enables personalized precision medicine, and curbs long-term healthcare spending. Robust growth drivers include a rising regional cancer burden, an aging demographic, high per-capita healthcare spending, and favorable reimbursement structures, along with rapid technological integration like AI-driven pathology tools. Key professional associations, such as the American Cancer Society (ACS), the American Society of Clinical Oncology (ASCO), and the Association for Molecular Pathology (AMP), play a pivotal structural role in this ecosystem. These organizations actively drive public health screening awareness campaigns, establish clinical practice guidelines for biomarker testing, advocate for research funding and diagnostic reimbursement policies, and foster interdisciplinary collaboration to translate cutting-edge diagnostic innovations seamlessly from the lab to routine patient care. Furthermore, strategic collaborations between research institutes and commercial enterprises continue to accelerate the translation of novel biomarkers into clinically validated tests. Meanwhile, ongoing expansions in public screening initiatives and private health insurance coverage are making high-throughput diagnostic platforms more accessible across both urban and rural healthcare settings. According to the research report, "North America Cancer Diagnostics Market Outlook, 2031," published by Bonafide Research, the North America Cancer Diagnostics Market was valued at more than 43.07 Billion in 2025.Major industry leaders including Roche Diagnostics, Thermo Fisher Scientific, Abbott Laboratories, Danaher Corporation, and Siemens Healthineers spearhead this landscape through constant innovation. Significant market developments highlight this dynamic growth, such as Roche’s non-invasive liquid biopsy assays for circulating tumor DNA, Thermo Fisher’s high-throughput next-generation sequencing (NGS) platforms for genomic profiling, and Abbott’s FDA-approved immunohistochemistry breast cancer biomarkers. Promising market opportunities lie in artificial intelligence-driven pathology software, companion diagnostics, and multi-cancer early detection (MCED) blood tests. A detailed supply chain analysis reveals an interconnected ecosystem: upstream suppliers provide specialized enzymes, specialized reagents, microfluidic chips, and semiconductor components; midstream manufacturers integrate these into automated diagnostic instruments and assay kits; and downstream distributors deliver products directly to hospitals, central reference laboratories, and outpatient oncology clinics for clinical patient processing. Furthermore, the region holds over a third of global market revenue, underscored by more than two million new cancer cases projected annually in the United States alone. However, supply chain vulnerabilities such as shortages of specialized rare-earth isotopes for imaging and high-grade chemical reagents routinely threaten operational stability. To mitigate these bottlenecks, lead players are increasingly nearshoring component manufacturing and establishing dual-sourcing models for critical microfluidic cartridges.
to Download this information in a PDF
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Dynamics
Market Drivers
• Rapid expansion of precision medicine and companion diagnostics: The paradigm shift from generalized cancer therapies to targeted, biomarker-driven oncology treatments is one of the strongest growth drivers in the region. Modern pharmaceutical development heavily relies on companion diagnostic (CDx) assays molecular or genomic tests required to determine whether a specific targeted therapy will benefit a patient. In North America, the US Food and Drug Administration (FDA) routinely approves targeted oncology drugs alongside mandatory companion diagnostic panels. Major health networks and guidelines (such as the National Comprehensive Cancer Network, or NCCN) now consider comprehensive biomarker testing mandatory prior to prescribing therapies for non-small cell lung cancer, colorectal cancer, and melanoma.• Rising cancer burden coupled with an aging demographic: Cancer risk correlates heavily with age, and North America’s shifting demographic profile acts as an organic catalyst for diagnostic test volume. With millions of individuals entering higher-risk age brackets, healthcare systems across the US and Canada are experiencing unprecedented demand for routine screening, early detection assays, and post-treatment monitoring. Furthermore, lifestyle risk factors, increased awareness campaigns, and government-backed screening initiatives (such as updated mammography, colonoscopy, and low-dose CT guidelines) prompt physicians to run frequent diagnostic, staging, and recurrence monitoring tests.
Market Challenges
• Complex reimbursement frameworks and high testing costs: Despite high per-capita healthcare spending in North America, navigating the regulatory and reimbursement ecosystem poses a formidable operational hurdle. Advanced diagnostic technologies such as comprehensive multi-gene Next-Generation Sequencing (NGS) panels and spatial biology platforms carry significant upfront development and clinical validation costs. Obtaining favorable Medicare Local Coverage Determinations (LCDs) and private health insurance coverage codes (CPT codes) for novel diagnostic assays is often a lengthy, unpredictable process.• Shortage of specialized pathologists and genetic professionals: The volume and structural complexity of modern diagnostic output have outpaced the availability of trained medical professionals capable of interpreting the results. Advanced diagnostic modalities generate dense, multi-layered data such as high-density genomic sequence variations, complex immunohistochemical staining patterns, and multi-parametric imaging sets. North America faces a well-documented shortage of certified anatomical pathologists, molecular geneticists, and clinical genetic counselors. This talent shortage creates operational bottlenecks in reference laboratories and hospital pathology departments, prolonging test turnaround times and limiting the seamless integration of cutting-edge diagnostic assays into routine clinical decisions.
Market Trends
• Widespread clinical integration of liquid biopsy and non-invasive diagnostics: A major trend in North American oncology is the transition from invasive tissue biopsies to non-invasive, blood-based diagnostic techniques. Liquid biopsy assays analyze circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes present in simple peripheral blood draws. This technology is gaining rapid adoption for early detection, minimal residual disease (MRD) monitoring, and tracking treatment resistance without subjecting frail patients to repeated tissue biopsy procedures. Regulatory clearances and expanded clinical validation for multi-cancer early detection (MCED) blood tests are positioning liquid biopsy as a disruptive, highly scalable standard of care across major cancer care centers.• Artificial intelligence integration in digital pathology and diagnostic imaging: Artificial intelligence (AI) and machine learning (ML) are rapidly evolving from experimental clinical tools to essential operational layers across North American cancer diagnostic workflows. In diagnostic radiology (MRI, CT, PET scans), AI algorithms assist clinicians by flagging subtle, early-stage micro-lesions, reducing false negatives, and accelerating image analysis. Concurrently, in digital pathology, high-throughput slide scanners combined with deep-learning image analysis software help quantify tissue biomarkers, identify tumor margins, and stratify risk profiles automatically.
Cancer Diagnostics Segmentation
| By Product Type | Consumables and reagents | |
| Instruments | ||
| By Technology | IVD testing | |
| Anatomic pathology | ||
| Diagnostic imaging | ||
| Biopsy | ||
| By Application | Breast Cancer | |
| Colorectal Cancer | ||
| Lung Cancer | ||
| Prostate Cancer | ||
| Others | ||
| By End User | Hospitals | |
| Diagnostic Centres | ||
| Research Institutes | ||
| Others | ||
| North America | United States | |
| Canada | ||
| Mexico | ||
Consumables and reagents occupy an important position in cancer diagnostics because nearly every laboratory-based diagnostic workflow depends on materials that are used, depleted, or replaced during testing. When a suspected tumor is investigated, laboratories may need reagents to preserve tissue, prepare microscopic slides, identify abnormal cells, detect cancer-associated proteins, extract DNA or RNA, and analyze genetic alterations. These materials support different diagnostic methods, including histopathology, immunohistochemistry, polymerase chain reaction, fluorescence in situ hybridization, and next-generation sequencing. The National Cancer Institute explains that cancer diagnosis often involves combining biopsy findings with laboratory investigations and additional biomarker testing rather than relying on one test alone. Each procedure requires appropriate materials, and different cancer types can require different combinations of reagents and assay components. For example, immunohistochemistry uses antibodies to identify specific proteins in tumor tissue, while molecular assays use enzymes, primers, probes, buffers, and other chemicals to detect selected genetic changes. Consumables such as collection tubes, pipette tips, reaction vessels, slides, cartridges, and specimen containers also help maintain sample integrity and reduce contamination. Unlike durable diagnostic instruments, these supplies must be replenished as testing continues, creating recurring procurement requirements for hospitals, pathology laboratories, reference laboratories, and specialized cancer centers. Quality and consistency are particularly important because reagent performance, sample handling, and laboratory procedures can affect whether a result is reliable and clinically interpretable. Laboratories also need validated materials that work with their established instruments and testing protocols, making dependable supply arrangements operationally significant. In vitro diagnostics has a central role in cancer care because many important diagnostic decisions depend on examining biological material outside the human body. IVD testing includes laboratory procedures that detect cellular abnormalities, proteins, genetic mutations, and other biological indicators associated with malignancy. The United States Food and Drug Administration explains that IVDs analyze samples such as blood and tissue and can also support precision medicine by identifying patients who may benefit from particular therapies. This broad clinical usefulness allows IVD methods to serve multiple stages of the cancer pathway, from investigating suspicious findings to establishing a diagnosis, determining tumor characteristics, and assessing relevant biomarkers. For example, blood counts can help investigate certain blood cancers, immunophenotyping can distinguish populations of abnormal cells, and molecular assays can identify genetic changes that influence treatment selection. Tissue-based immunohistochemistry can identify proteins such as estrogen receptors, progesterone receptors, and HER2 in breast cancer, helping clinicians classify tumors and select appropriate treatment options. The segment's established laboratory infrastructure is another important factor. Hospitals, independent diagnostic laboratories, academic medical centers, and reference laboratories already use automated analyzers, molecular platforms, validated protocols, and trained personnel to process specimens. This existing foundation makes it possible to incorporate additional assays into clinical workflows without replacing every part of the diagnostic system. Its growth potential also reflects the increasing importance of molecular characterization and precision oncology, in which the biological features of a tumor can influence the choice of targeted medicines or other therapies. The National Cancer Institute notes that biomarker testing is routinely used for treatment decisions in certain cancers, including breast, colorectal, and non-small-cell lung cancer. Breast cancer occupies a prominent position in cancer diagnostics because its clinical management involves a well-established sequence of screening, imaging, tissue confirmation, tumor classification, and treatment-related testing. In the United States, mammography is the standard screening method for most women in the recommended screening population, and the US Preventive Services Task Force recommends screening every two years for women aged 40 to 74 at average risk. The Centers for Disease Control and Prevention explains that mammography can detect abnormalities before they become noticeable through physical symptoms, allowing further investigation when necessary. An abnormal mammogram does not automatically mean that cancer is present; diagnostic assessment may require additional imaging and a biopsy. When tissue is collected, pathologists examine its cellular characteristics to determine whether malignancy exists and to identify the specific tumor type. This creates demand for multiple complementary diagnostic procedures rather than a single screening test. After breast cancer is confirmed, additional laboratory testing can establish clinically important tumor characteristics. The National Cancer Institute identifies estrogen receptor, progesterone receptor, and HER2 testing as examples of biomarker investigations included in the assessment of breast cancer, with findings helping clinicians determine which treatments may be appropriate. These investigations may involve immunohistochemistry, in situ hybridization, and other molecular techniques, requiring specialized reagents, laboratory instruments, and trained pathology professionals. Breast cancer diagnostics also extends beyond initial detection because patients may undergo additional testing when disease characteristics need clarification, when treatment decisions change, or when recurrence is suspected. Screening recommendations and diagnostic pathways create an organized clinical framework that supports the repeated use of established testing technologies. Hospitals play a leading role in cancer diagnostics because patients with suspected malignancies frequently need several investigations before clinicians can establish a diagnosis and determine the next steps in care. A patient may initially present with symptoms, an abnormal imaging result, or a finding from a screening program, but confirming cancer often requires a combination of clinical assessment, laboratory analysis, imaging, and tissue examination. The National Cancer Institute explains that a biopsy is frequently necessary to establish a definitive diagnosis and that pathologists examine collected tissue to produce reports describing the cancer and its characteristics. Hospitals are particularly well positioned to coordinate these activities because they can connect radiology departments, surgical services, pathology laboratories, oncology specialists, and other clinical teams. For example, a suspicious breast lesion may require diagnostic mammography, ultrasound-guided biopsy, histopathological examination, and receptor testing before a treatment plan can be finalized. Similar coordinated pathways apply to lung, gastrointestinal, and other cancers, although the exact investigations differ by disease. Hospitals also manage patients who require urgent assessment, inpatient procedures, surgery, or evaluation of complications, creating diagnostic requirements beyond routine screening. Larger medical centers and academic hospitals may additionally provide molecular pathology, genomic profiling, hematopathology, and specialist consultations for complex cases. These services depend on trained personnel, validated laboratory methods, appropriate specimen handling, and reliable supplies of reagents and consumables. Hospitals may conduct testing internally or send specimens to external reference laboratories, so their end-user importance does not mean that every diagnostic procedure occurs within hospital premises. Their purchasing decisions are also shaped by equipment compatibility, quality-control requirements, turnaround times, clinical accreditation, and procurement arrangements. The National Cancer Institute identifies hospitals and medical centers among the institutions involved in advancing cancer diagnostic research and technology.
to Download this information in a PDF
Cancer Diagnostics Market Regional Insights
The United States occupies a leading position in North American cancer diagnostics because its healthcare infrastructure supports a wide range of diagnostic activities, from routine screening and conventional pathology to specialized molecular investigations. Hospitals, community healthcare facilities, independent laboratories, academic medical centers, and dedicated cancer institutes collectively provide multiple points at which patients can enter the diagnostic pathway. The country also has established screening recommendations for several cancers, including breast and colorectal cancer, while cervical cancer screening uses established methods such as human papillomavirus testing and Pap testing. These programs help identify individuals who require further assessment, creating a continuing need for diagnostic imaging, laboratory analysis, biopsies, and pathology services. Another important factor is the role of the United States in the development and clinical implementation of advanced diagnostic technologies. The National Cancer Institute supports research into diagnostic biomarkers, novel in vitro diagnostics, specimen characterization, and methods intended to improve clinical decision-making. Its work connects research institutions, hospitals, universities, and businesses involved in cancer diagnostics. The country's established laboratory capabilities also facilitate the use of immunohistochemistry, molecular assays, genomic profiling, and other tests that help characterize tumors and inform treatment selection. For example, biomarker testing can identify biological features relevant to targeted therapies, while molecular analysis can detect selected genetic alterations in tumor samples. These activities require trained pathologists, laboratory scientists, validated testing procedures, specialized instruments, and a reliable supply of reagents and consumables. In addition, the presence of academic hospitals and specialized cancer centers supports complex diagnostic cases that may require multidisciplinary review or additional molecular investigation. However, access to advanced testing is not uniform across all communities, and insurance coverage, affordability, laboratory availability, and geographic differences can affect patient access. The United States also operates alongside Canada's healthcare and research systems, which contribute to the broader regional market.
to Download this information in a PDF
Companies Mentioned
- Abbott Laboratories
- Danaher Corporation
- Siemens Healthineers
- Agilent Technologies, Inc.
- Thermo Fisher Scientific Inc
- QIAGEN N.V.
- Illumina, Inc
- Hologic, Inc.
- Becton, Dickinson and Company
- Roche Holding AG
- bioMérieux SA
- Foundation Medicine, Inc.
Table of Contents
- 1. Executive Summary
- 2. Market Dynamics
- 2.1. Market Drivers & Opportunities
- 2.2. Market Restraints & Challenges
- 2.3. Market Trends
- 2.4. Supply chain Analysis
- 2.5. Policy & Regulatory Framework
- 2.6. Industry Experts Views
- 3. Research Methodology
- 3.1. Secondary Research
- 3.2. Primary Data Collection
- 3.3. Market Formation & Validation
- 3.4. Report Writing, Quality Check & Delivery
- 4. Market Structure
- 4.1. Market Considerate
- 4.2. Assumptions
- 4.3. Limitations
- 4.4. Abbreviations
- 4.5. Sources
- 4.6. Definitions
- 5. Economic /Demographic Snapshot
- 6. North America Cancer Diagnostics Market Outlook
- 6.1. Market Size By Value
- 6.2. Market Share By Country
- 6.3. Market Size and Forecast, By Product Type
- 6.4. Market Size and Forecast, By Technology
- 6.5. Market Size and Forecast, By Application
- 6.6. Market Size and Forecast, By End User
- 6.7. United States Cancer Diagnostics Market Outlook
- 6.7.1. Market Size by Value
- 6.7.2. Market Size and Forecast By Product Type
- 6.7.3. Market Size and Forecast By Technology
- 6.7.4. Market Size and Forecast By Application
- 6.8. Canada Cancer Diagnostics Market Outlook
- 6.8.1. Market Size by Value
- 6.8.2. Market Size and Forecast By Product Type
- 6.8.3. Market Size and Forecast By Technology
- 6.8.4. Market Size and Forecast By Application
- 6.9. Mexico Cancer Diagnostics Market Outlook
- 6.9.1. Market Size by Value
- 6.9.2. Market Size and Forecast By Product Type
- 6.9.3. Market Size and Forecast By Technology
- 6.9.4. Market Size and Forecast By Application
- 7. Competitive Landscape
- 7.1. Competitive Dashboard
- 7.2. Business Strategies Adopted by Key Players
- 7.3. Porter's Five Forces
- 7.4. Company Profile
- 7.4.1. Thermo Fisher Scientific Inc.
- 7.4.1.1. Company Snapshot
- 7.4.1.2. Company Overview
- 7.4.1.3. Financial Highlights
- 7.4.1.4. Geographic Insights
- 7.4.1.5. Business Segment & Performance
- 7.4.1.6. Product Portfolio
- 7.4.1.7. Key Executives
- 7.4.1.8. Strategic Moves & Developments
- 7.4.2. Abbott Laboratories
- 7.4.3. Agilent Technologies, Inc.
- 7.4.4. Roche Diagnostics
- 7.4.5. Danaher Corporation
- 7.4.6. Siemens Healthineers AG
- 7.4.7. QIAGEN N.V.
- 7.4.8. Becton, Dickinson and Company (BD)
- 7.4.9. Illumina, Inc.
- 7.4.10. Hologic, Inc.
- 7.4.11. bioMérieux SA
- 7.4.12. Foundation Medicine, Inc.
- 8. Strategic Recommendations
- 9. Annexure
- 9.1. FAQ`s
- 9.2. Notes
- 10. Disclaimer
Table 2: Top 10 Counties Economic Snapshot 2024
Table 3: Economic Snapshot of Other Prominent Countries 2022
Table 4: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 5: North America Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 6: North America Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 7: North America Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 8: North America Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 9: United States Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 10: United States Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 11: United States Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 12: Canada Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 13: Canada Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 14: Canada Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 15: Mexico Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 16: Mexico Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 17: Mexico Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 18: Competitive Dashboard of top 5 players, 2025
Figure 2: North America Cancer Diagnostics Market Share By Country (2025)
Figure 3: United States Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 4: Canada Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: Mexico Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 6: Porter's Five Forces of Global Cancer Diagnostics Market
Cancer Diagnostics Market Research FAQs
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Our Clients
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (27 October, 2026)
- Notify To Team (27 October, 2026)
- Report updation (28 October, 2026)
- Report Quality Check (28 October, 2026)
- Report Dispatch (29 October, 2026)
- Hard Copy
Recently Viewed Products
North America Cancer Diagnostics Market Outlook, 2031
We are friendly and approachable, give us a call.